Rationale: Chemotherapy administration before a donor stem cell transplant is necessary to stop the patient's immune system from rejecting the donor's stem cells. When healthy stem cells from a donor are infused into the patient, the donor white blood cells can provide the missing enzyme that causes the metabolic disease. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving a monoclonal antibody, alemtuzumab, before transplant and cyclosporine and mycophenolate mofetil before and after transplant may stop this from happening. This may be an effective treatment for inherited metabolic disorders. Purpose: The design of this study is to achieve donor cell engraftment in patients with standard-risk inherited metabolic diseases with limited peri-transplant morbidity and mortality. This will be achieved through the administration of the chemotherapy regimen described. The intention is to follow transplanted patient for years after transplant monitoring them for complications of their disease and assisting families with a multifaceted interdisciplinary approach.
Primary Objective: * To estimate the proportion of patients with donor derived engraftment at day 100 post transplant as defined by 80% or greater donor cells in the CD3 (T cell) fraction Secondary Objectives: * To determine the incidence and severity of graft-versus-host disease (GVHD) by day 100 * To determine the incidence of peri-transplant mortality (death by day 100) * To monitor donor cell chimerism at various time points following allogeneic transplantation with this transplant regimen as determined at day 28, 42, 100, 6 months and yearly for 5 years.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
46
Administered Days -21, -20 and -19, 0.3 mg/kg subcutaneously (SQ) or intravenously (IV)
Administered days -10 through -6, 50 mg/kg/day intravenous (IV) over 2 hours - with Mesna continuous infusion or 5 times daily.
Administered every 6 hours: If \< or = 12 kg then 1.1 mg/kg/dose intravenous (IV). If \> 12 kg then 0.8 mg/kg/dose IV
Administered \> 24 hours after last dose of busulfan.
2.5 mg/kg/dose intravenous (IV\_ beginning on day -3. Frequency of daily dosing will be based on the recipient's body weight: * If body weight is ≤ 40 kg dosing will be 3 times daily * If body weight is \> 40 kg dosing will be 2 times daily An attempt will be made to maintain a trough cyclosporine level of 250 mg/L to 350 mg/L. Once the patient can tolerate oral medications and has a normal gastrointestinal transit time, CsA will be converted to an oral form at a dose 2 times the current IV dose (maximum 12.5 mg/kg/day as initial oral dose).
15 mg/kg/dose (max dose of 1gram) IV three times a day beginning on Day -3 at a dose based on body weight: The same dosage is used orally or intravenously. Stop MMF at day +42 or 7 days after engraftment achieved (ANC\>500 x 10\^6 neutrophils/L x 3 days and chimerism \>90%), whichever is later.
Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States
Number of Patients With Donor Derived Engraftment
Donor derived engraftment is defined as 80 percent or greater donor cells in the recipient's bone marrow and blood cells.
Time frame: Day 100 Post Transplant
Number of Patients With Grade 0 Graft-Versus-Host Disease (GVHD)
GVHD grading is performed using modified Glucksberg criteria and is as follows: grade 0: absence of any skin, liver and/or gastrointestinal (GI) involvement grade 1: skin stage 1 or 2 only grade 2: skin stage 3 or liver stage 1 or lower GI stage 1 or upper GI involvement grade 3: skin stage 0 - 3 plus liver stage 2-4 or lower GI stage 2-3 grade 4: skin stage 4 or lower GI stage 4
Time frame: Day 100 Post Transplant
Number of Patients With Grade 1 Graft-Versus-Host Disease (GVHD)
GVHD grading is performed using modified Glucksberg criteria and is as follows: grade 0: absence of any skin, liver and/or gastrointestinal (GI) involvement grade 1: skin stage 1 or 2 only grade 2: skin stage 3 or liver stage 1 or lower GI stage 1 or upper GI involvement grade 3: skin stage 0 - 3 plus liver stage 2-4 or lower GI stage 2-3 grade 4: skin stage 4 or lower GI stage 4
Time frame: Day 100 Post Transplant
Number of Patients With Grade 2 Graft-Versus-Host Disease (GVHD)
GVHD grading is performed using modified Glucksberg criteria and is as follows: grade 0: absence of any skin, liver and/or gastrointestinal (GI) involvement grade 1: skin stage 1 or 2 only grade 2: skin stage 3 or liver stage 1 or lower GI stage 1 or upper GI involvement grade 3: skin stage 0 - 3 plus liver stage 2-4 or lower GI stage 2-3 grade 4: skin stage 4 or lower GI stage 4
Time frame: Day 100 Post Transplant
Number of Patients With Grade 3 Graft-Versus-Host Disease (GVHD)
GVHD grading is performed using modified Glucksberg criteria and is as follows: grade 0: absence of any skin, liver and/or gastrointestinal (GI) involvement grade 1: skin stage 1 or 2 only grade 2: skin stage 3 or liver stage 1 or lower GI stage 1 or upper GI involvement grade 3: skin stage 0 - 3 plus liver stage 2-4 or lower GI stage 2-3 grade 4: skin stage 4 or lower GI stage 4
Time frame: Day 100 Post Transplant
Number of Patients With Grade 4 Graft-Versus-Host Disease (GVHD)
GVHD grading is performed using modified Glucksberg criteria and is as follows: grade 0: absence of any skin, liver and/or gastrointestinal (GI) involvement grade 1: skin stage 1 or 2 only grade 2: skin stage 3 or liver stage 1 or lower GI stage 1 or upper GI involvement grade 3: skin stage 0 - 3 plus liver stage 2-4 or lower GI stage 2-3 grade 4: skin stage 4 or lower GI stage 4
Time frame: Day 100 Post Transplant
Number of Patients Who Died Peri-Transplant
Peri-transplant is defined as within 100 days of transplant.
Time frame: By Day 100 Post Transplant
Donor Cell Chimerism Following Transplant
Donor cell chimerism is defined as the percentage of bone marrow and blood cells in the recipient that are of donor origin.
Time frame: Day 28
Donor Cell Chimerism Following Transplant
Donor cell chimerism is defined as the percentage of bone marrow and blood cells in the recipient that are of donor origin.
Time frame: Day 42
Donor Cell Chimerism Following Transplant
Donor cell chimerism is defined as the percentage of bone marrow and blood cells in the recipient that are of donor origin.
Time frame: Day 100
Donor Cell Chimerism Following Transplant
Donor cell chimerism is defined as the percentage of bone marrow and blood cells in the recipient that are of donor origin.
Time frame: 6 months
Donor Cell Chimerism Following Transplant
Donor cell chimerism is defined as the percentage of bone marrow and blood cells in the recipient that are of donor origin.
Time frame: One year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.